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Background: Around 40 % of individuals with eating disorders of recurrent binge eating, namely bulimia nervosa and
binge eating disorder, are obese. In contrast to binge eating disorder, currently there is no evidence base for weight
management or weight loss psychological therapies in the treatment of bulimia nervosa despite their efficacy in binge
eating disorder. Thus, a manualised therapy called HAPIFED (Healthy APproach to weIght management and Food in
Eating Disorders) has been developed. HAPIFED integrates the leading evidence-based psychological therapies, cognitive
behavioural therapy-enhanced (CBT-E) and behavioural weight loss treatment (BWLT) for binge eating disorder and
obesity respectively. The aim of the present study is to detail the protocol for a randomised controlled trial (RCT) of
HAPIFED versus CBT-E for people with bulimia nervosa and binge eating disorder who are overweight/obese.
Method/Design: A single-blind superiority RCT is proposed. One hundred Brazilian participants aged≥ 18 years, with a
diagnosis of bulimia nervosa or binge eating disorder, BMI > 27 to < 40 kg/m2, will be recruited from both community
and clinics and individually randomised to a therapy arm. Five groups of ten participants will receive the experimental
intervention (HAPIFED) and the other five groups of ten the control intervention (CBT-E). Both therapies are manualised,
and in this RCT will comprise 1 individual session and 29 office-based group sessions over 6 months. Assessment points
will be at baseline, end of therapy, and 6 and 12 months after end of therapy. The primary outcome of this intervention
will be reduced weight. Secondary outcomes will be improved metabolic indicators of weight management, reduction
in eating disorder symptoms including improved control over eating, improved adaptive function, physical and mental
health-related quality of life, and reduced levels of depression and anxiety.
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Discussion: This study will be the first to investigate a psychological therapy that aims to assist weight management in
people with co-morbid overweight or obesity bulimia nervosa as well as with binge eating disorder. It will
have the potential to improve health outcomes for the rapidly increasing number of adults with co-morbid
obesity and binge eating disorder or bulimia nervosa.
Trial registration: US National Institutes of Health clinical trial registration number NCT02464345, date of
registration 1 June 2015.
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The combined general population lifetime prevalence of
bulimia nervosa (BN) and binge eating disorder (BED) is
around 5 % in women and 3 % in men [1]. Both disor-
ders are characterised by recurrent binge eating or un-
controlled overeating episodes which, in the case of BN
are also associated with regular compensatory weight
control behaviours (e.g., self-induced vomiting) [2, 3]. It
is now recognised that an increasing number, now
around 40 % of people in the community with BN or
with BED are obese [4, 5]. In clinics the prevalence is
even higher, up to 80 % [6, 7]. Bulik et al. suggested, in a
paper to highlight the issues of managing weight and
eating disorders, that ‘BN in the overweight and obese
patients may represent the natural evolution of the eat-
ing disorder on the backdrop of the obesity epidemic’
(Bulik et al., p.6) [8]. They wrote about the increase in
clinical presentations of overweight and obese patients
with BN and their requests for help with weight man-
agement. They argued that due to the rise in combined
prevalence of co-morbid obesity and BN and BED, and
their shared risk and maintaining features, an urgent
need for new approaches to management is needed [8].
Patients with co-morbid BN or BED and obesity are
currently faced with a problematic choice. Community-
based studies [9, 10] indicate that while individuals with
BN and BED frequently seek help in order to lose
weight, most evidence-based psychological treatments
such as cognitive behavioural therapy (CBT) for eating
disorders fail to aid weight loss [11, 12]. In one study,
Brody et al. [13] found the majority (63 %) of people
with BED and co-morbid obesity chose CBT over a be-
havioural weight loss treatment (BWLT). However, 50 %
of those who chose BWLT also thought their primary
problem was BED and not obesity. Individuals with BN
or BED and obesity may consequently undergo years of
treatment for weight loss without attention to binge
eating and its associated psychological co-morbidities
[14, 15]. Further, whilst approaches such as BWLT for
obesity are associated with weight loss in BED, weight
regain is common [8] and whereas dietary restriction in
normal weight people, with BN risks exacerbating the
cycle of bingeing and fasting, as suggested by the classicKeys study of starvation [16], this may well differ for dietary
restriction that is part of a supervised BWLT programme in
people who are obese. As Bulik discussed, there may actu-
ally be harm from not addressing unchecked obesity [8]. A
recent systematic review suggests that even very high levels
of dietary restriction, as in low or very low energy diets, do
not exacerbate binge eating, at least in BED [17]. Individ-
uals with binge eating and obesity seek help to lose weight,
but further research to establish the safety of weight loss
treatment in BN is needed. In sum, BWLT fail to address
the eating disorder and conversely psychological treatments
fail to aid weight loss.
To address the need for treatment of BN and BED
co-morbid with obesity, a manualised therapy called a
Healthy APproach to weIght management and Food
in Eating Disorders (HAPIFED) was developed (da
Luz et al., manuscript in preparation). This therapy
aims to integrate features of the leading evidence-based
psychological therapies for BN and BED, CBT-enhanced
(CBT-E) [18, 19] with a specific BWLT for weight loss and
reduced binge eating in BED [20, 21]. In HAPIFED, like
BWLT, dietary restriction and weight loss goals are mod-
est (around 5 % of percent body weight) and a healthy life-
style is promoted together with attention to the role of
nutrition, food and eating in mood regulation. As recom-
mended by Bulik et al. and Sainsbury-Salis [8, 22], internal
appetite regulation and self-awareness of hunger and
satiety cues are favoured over external regulation of
food intake, and approaches are also informed by an
understanding of effects of energy restriction [22].
HAPIFED differs from CBT-E in including obesity risk
and maintaining factors in the personalised formulation,
psychoeducation for obesity, self-monitoring of appetite
regulation, weight loss management via behavioural acti-
vation and promotion of physical activity with the partici-
pation of a multidisciplinary team (psychologist, dietitian,
physician and occupational or activity therapist). An im-
portant feature of HAPIFED is also the increased number
of sessions (30), and the treatment period of 6 months,
which is one third more sessions and 2 months longer
than usual CBT-E [18].
Table 1 shows the similarities and differences between
CBT-E and HAPIFED. To avoid bias from effects of
Table 1 Similarities and differences between the trial therapies
Included HAPIFED CBT-E
Personalised ED CBT
formulation
Yes, includes obesity Yes, ED only
Psychoeducation Yes, ED and obesity Yes, ED only
Nutritional counselling Yes, dietician led Yes, not dietician led
Behavioural monitoring Yes, with appetite cues Yes
Multidisciplinary Yes No
Session (number)/duration
(months)
30/6 30/6
Weight loss management
included
Yes No
Behavioural activation Yes No
‘Healthy’ exercise
encouraged
Yes No
Emotion regulation skills Yes Yes
CBT cognitive behavioural therapy, CBT-E cognitive behavioural therapy-enhanced,
ED eating disorders, HAPIFED Healthy Approach to WeIght management and Food
in Eating Disorders
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trial (RCT), the CBT-E broad version will be used, which
may be extended to 30 sessions, and has additional
modules addressing psychological- maintaining factors,
namely clinical perfectionism, core low self-esteem and
interpersonal problems [18].
The primary aim of this paper is to detail the protocol
(version registered as at 11 July 2015) of a single-blind
superiority RCT that compares HAPIFED with CBT-E
in weight loss efficacy. A second aim will be to investi-
gate the safety of the introduction of weight loss man-
agement particularly for people with BN, but also for
those with BED who are overweight/obese.
The primary hypothesis of the RCT will be that at
end-of-treatment, 6-month and 12-month follow-up,
participants receiving HAPIFED will have lost more
body weight than those receiving CBT-E. Secondary hy-
potheses will be that participants receiving HAPIFED
compared to CBT-E group will have significantly im-
proved indicators of weight management e.g., reduced
body waist measurement, improved cardiovascular and
metabolic status, and that participants in either group
who achieve binge eating remission will achieve a greater
degree of weight loss.
Method/Design
Participants
This study will comprise 100 participants recruited from
both community and clinics. Assessments and therapy
will be conducted in the Eating Disorders Programme
(PROATA) clinic in the Department of Psychiatry of the
Federal University of São Paulo (UNIFESP), Brazil. The
inclusion criteria are: age ≥ 18 years; either sex; a pri-
mary eating disorder diagnosis of BN or BED typeaccording to the Diagnostic and Statistical Manual of
Mental Disorders, fifth edition (DSM-5) and/or the pro-
posed International Classification of Diseases, eleventh
version (ICD-11) criteria [2, 3]; and a body mass index
(BMI) ≥ 27 and < 40 kg/m2. The exclusion criteria are: a
current diagnosis of psychosis or bipolar disorder and/or
a high level of suicide risk; use of weight loss medication;
history of bariatric surgery; clinical conditions that interfere
with appetite regulation (e.g., Prader-Willi and Cushing
syndromes); and currently receiving psychological treat-
ment for eating disorders.
The present study a priori power analysis was based
on the estimate of a moderate between group effect size
(i.e., 0.6) in the primary outcome of weight loss. To
achieve this with power of 0.8 and 1-tailed alpha p < 0.05,
a minimum of 36 participants per group is required
according to Cohen’s tables. Allowing for attrition the
sample size is 50 per arm and 10 per therapy group.
Procedure
Recruitment will take place between June 2015 and
December 2016. The recruitment will be through
PROATA’s treatment waiting list, printed notices and
broadcasting of written and oral media. The first con-
tact will be made by the research team by phone or
Email. Those who will be considered eligible for the
study will be invited for a first interview at which point
informed written consent will be completed, inclusion
and exclusion criteria confirmed, and a medical history
and physical examination including height and weight
(with calibrated scale) undertaken. Medical assessment
will accord with international guidelines for weight loss
management. Laboratory tests will be circulating fasting
lipid profile, fasting glucose matched with insulin, liver
function, electrolytes, urea, uric acid and creatinine. A
semi-structured interview and self-report questionnaires
to determine the eating disorder and co-morbid diagnoses
and suicide risk will be conducted. A second appointment
will be scheduled for a semi-structured interview that
confirms the eating disorder diagnosis and completes a
detailed assessment of eating disorder symptoms and
behaviours (as detailed in the study timeline on Table 2).
Single blinding will be achieved by not informing par-
ticipants of any specific details of the therapy content.
The information at recruitment that will be provided to
participants regarding the therapy is as follows: ‘We have
developed an approach that integrates techniques from
cognitive behavioural therapy for eating disorders with
behavioural strategies for weight loss. One is called
HAPIFED (a Healthy Approach to Weight Management
and Food in Eating Disorders), and the other is called
cognitive behavioural therapy-enhanced … If you agree
to participate in this study and have met all the inclusion
criteria and if outpatient therapy is suitable for you, you
Table 2 Timetable of administration of assessment measures
Baseline Mid-treatment End-oftreatment Follow-up (6 and 12 months)
Demographic questionnaire ✓
Mini International Neuropsychiatric Interview ✓
Anthropometrya ✓ ✓ ✓ ✓
Eating Disorder Examination ✓ ✓ ✓
Eating Disorder Examination Questionnaire ✓ ✓ ✓ ✓
Other self-report measuresb ✓ ✓ ✓ ✓
Adaptive function self-report measuresc ✓ ✓ ✓
Physical state biomarkersd ✓ ✓
Client satisfaction and success of blinding questions ✓ ✓
aWaist and hip circumferences, pulse and sitting blood pressure, height and weight for BMI calculation; BMI is also monitored weekly in session
bLOCES, BES, DASS21
cSF-12: ‘days out of role’
dFasting blood glucose, insulin, lipid profile, liver function test, electrolytes, urea, creatinine and uric acid
BES Binge Eating Scale, BMI body mass index, DASS-21 Depression, Anxiety and Stress Scale-21, LOCES Loss of Control Over Eating Scale, SF-12 12-item Short Form
Health Survey
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to a group therapy programme that will comprise twice-
weekly group over about 1 month … You will have an
equal chance (like tossing a coin) of participation in one or
other treatment’ (translated from Brazilian Portuguese by
author PH). Participants will not be informed if they
will be in a HAPIFED or in a CBT-E therapy group
at any point, and any treatment materials provided to
participant will not be identified as being from either
HAPIFED or CBT-E manuals.
Those who will be considered eligible for the study
will be randomised in blocks of 20 (2 therapy groups)
using an online site (www.sealedenvelope.com). One
hundred participants will be allocated over 18 months to
10 groups with 10 participants in each group. Five
groups will receive HAPIFED (experimental group) and
five will receive CBT-E (control group). An investigator
external to the site (PH) will administer the allocation
which will be concealed and revealed only to trial thera-
pists and therapy supervisors until the final participant
completes follow-up.
Description of interventions
HAPIFED has 5 stages that comprise 1 individual initial
clinical assessment session (session 1) with a psychologist
followed by 29 × 90-minute group office-based meetings
twice weekly for 4 weeks, then weekly, with 2 psycholo-
gists over a total of 6 months. These include four conjoint
sessions, two with a dietician and psychologist, one with
an occupational therapist, and one psychoeducational ses-
sion introducing internal hunger and satiety monitoring
with a medical doctor. All conjoint sessions are within the
first stage of therapy (sessions 2–11). In addition, the oc-
cupation therapist will make 2 domiciliary (home) visits
(in the 5th and 13th weeks of treatment) and 1 phone call
contact (between sessions 21 and 22) to each participant.The aim of these visits is to assess the environment and
weight-maintaining habits within the home context. The
occupational therapist will formulate a personalised be-
havioural change programme that will identify opportun-
ities and propose modifications to daily routines to
increase physical activity levels and improve relationships
with food preparation and consumption. Where severe
body image distress has prevented physical activity in
front of other people, the occupational therapist will sup-
port the participant in physical activity around others and
practice techniques discussed with the psychologist to use
in relevant situations (e.g., how to cope with situations
when feeling stigmatised). The phone call is to check
progress since the home visits.
Stage 1 (sessions 2–11) begins with psychoeducation
that includes information on why ‘diets’ fail, non-hungry
and hungry eating, and reviewing the individual’s eating
disorder, weight history, family, and medical history rele-
vant to determining both the likelihood of gaining or
losing weight with treatment and obesity-related health
risks. Information about eating disorders and an intro-
duction to the CBT formulation of the development of
the eating disorder are provided. In addition to disor-
dered eating (bingeing, attempted or actual fasting) and
compensatory behaviours (e.g., fasting, vomiting, com-
pulsive exercise), it incorporates weight history and the
role of life events and mood intolerance; and, where
relevant, interpersonal deficits, low self-esteem and clin-
ical perfectionism. In-session weighing, regular eating
and monitoring of key behaviours are introduced. Ses-
sion 4 includes a presentation on appetite regulation and
the rationale for an approach of modifying eating ac-
cording to internal cues, as outlined in the book The
Don’t Go Hungry Diet [22]. Specific steps are outlined to
help participants lose weight by listening to their appe-
tite, including hunger and satiety scores that are used to
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creasing fruit and vegetable intake and physical activity.
This is an alternate to a conventional weight loss
programme, which is based on external measures of
control (e.g., counting portion size/number) and explicit
messages about restriction (e.g., reduce fat, etc.). In ses-
sion 6 there is a motivational talk from the occupational
therapist, and pedometers are provided to promote
physical activity. The pedometer will measure the level
of activity participants have in their usual routine as well
as increase their awareness of their activity levels. After
session 19 the pedometers are provided again to check
whether they have been able to make improvements in
their routine level of activity as well as a reminder of this
need. The pedometers will be proposed to be used for
5 days (3 weekdays and 2 weekend days).
Stage 2 (session 12) is a brief ‘reformulation’ time and
for personalisation of the formulation. Stage 3 (sessions
13–-19) has an emphasis on behavioural activation and
activity monitoring while also addressing the key behav-
iours and training in specific behavioural skills. Monitor-
ing of key eating and related behaviours (including binge
eating, exercise and urge to exercise, other compensa-
tions such as vomiting, and body checking) continues
with concomitant ratings of mood and appetite, with an
additional emphasis on behavioural activation and activ-
ity monitoring. Approaches include appetite-focussed
CBT techniques. Monitoring is based more on appetite
cues than food monitoring. This aims to direct attention
away from an excessive focus on type of food [23]. Be-
havioural experiments are introduced to prevent eating
disorder behaviours, establish regular meal patterns and
promote self-control. In this stage, nutritional education
and counselling and exercise are addressed. The partici-
pants will work to make lifestyle changes to establish
more healthy eating and physical activity patterns, and
food choices which are less than sufficient to meet en-
ergy needs, in order to bring about modest, at least 5 %,
of previous body weight loss. This is a level known to
improve health outcomes [24]. Exercise is addressed
using behavioural activation strategies. Stage 4 (sessions
20–27) introduces Socratic questioning and challenging
of beliefs and attitudes which reinforce eating disorder
behaviours, such as valuing oneself according to one’s
weight and shape, and ‘all or nothing’ dichotomous think-
ing. Problem-solving is also incorporated here. Mood in-
tolerance is addressed with training in specific emotion
regulation skills. Behavioural experiments and the appetite-
awareness and physical activity plan from phase 2 continue
in this phase. Stage 5 (sessions 28–30): as in CBT, the final
sessions of HAPIFED involve relapse prevention including
reviewing strategies that have successfully helped. By the
end of therapy, the goal is to achieve a regular pattern of
eating, of varied and appropriately sized food portions,with mild to modest energy restriction. Binge eating and
self-induced vomiting and other behaviours are intended
to be reduced or absent, and food, eating and weight are
envisaged to no longer dominate the patient’s self-view.
Four group follow-up sessions over the subsequent
6 months are also offered to participants. These sessions
are conducted by the psychologists who led the group.
The aim is to address relapses, review ongoing progress
and promote continued improvement.
The comparison intervention is the standard lead-
ing evidence-based therapy for BN and BED, CBT-E
[25–27]. In this study the broad version of CBT-E [18]
with additional mood intolerance and other modules will
be used and will match HAPIFED in session duration and
number. There will be 1 individual session at the start of
treatment plus 29 group sessions over 6-months in this
RCT. CBT-E uses therapists from a single discipline, in
this study, psychology. CBT for BED and BN has been
used successfully in a group format [28, 29].
The structure of HAPIFED has been based on the
structure of CBT-E. CBT-E [18] is organised in four
stages. Stage 1 (sessions 0–-7) comprises twice-weekly
appointments which aim to engage the patient with the
treatment, create the formulation, provide information
and introduce in-session weighing and regular eating.
Stage 2 (sessions 8–9) encompasses the revision of the
progress and of the formulation, trying to identify any
difficulty to proceed. Stage 3 (sessions 10–17) addresses
the mechanisms that maintain the symptomatology and
the last stage (sessions 18–20) prepares the patient to
continue the progress obtained by the treatment.
Outcomes
The primary outcome of this intervention will be a re-
duced body weight sustained to 12 months after comple-
tion of the intervention. Secondary outcomes will be (i)
improved metabolic indicators of weight management;
(ii) reduction in eating disorder symptoms, namely binge
eating, loss of control over eating, driven exercise, purging,
and self-induced vomiting and dysfunctional cognitions
(weight and shape overvaluation and eating concerns);
(iii) being less than 1 standard deviation above the
community mean for global score on the Eating Disorder
Examination (EDE) [18]; (iv) improved adaptive function
(‘days out of role’), physical and mental health-related
quality of life (HRQoL); and (v) reduced levels of depres-
sion and anxiety.
Assessment
Participants will be assessed 4 times: at baseline,
6 months (end of therapy), 12 months (6 months after
end of therapy) and 18 months (1 year after end of ther-
apy). Assessments will be conducted on all participants
including those who do not complete treatment.
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CB1.1. A self-report questionnaire will be used to assess
sociodemographic and clinical variables (age,
gender, race, occupation, marital status,
education, eating disorder onset and lifetime
history of eating disorders) and will include a
specific questionnaire to determine income
status, namely the ‘Critério de Classificação
Econômica Brasil 2014’ [30].
1.2. Mini International Neuropsychiatric Interview
(MINI). The MINI is a reliable and valid
structured interview for psychiatric diagnoses
according to the DSM [2]. Only the MINI-5 [31]
for DSM-IV [32] is translated into Portuguese.
Thus, the MINI-5 will be used in this study, with
modifications to the coding of all disorders to
accord with DSM-5 diagnoses as in the
MINI-7 [33].
2. Measures repeated from baseline to 12-month
follow-up:
2.1. Anthropometry will include waist and hip
circumferences (mean of 3 measures), pulse and
sitting blood pressure. Height and weight will be
measured with a stadiometer and calibrated
scale, from which BMI (kg/m2) will be
calculated.
2.2. Eating disorder psychopathology instruments:ble 3
mester
ages
PIFED
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T-E cog2.2.1. Eating Disorder Examination Edition 17.0D
[34]: the EDE is the ‘gold standard’
semi-structured interview used to assess
eating disorder symptoms and diagnoses.
Four subscales can be derived measuringTime schedule for the randomised controlled trial
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and CBT-E groups 3 and 4 Recruitment and intervention x
and CBT-E groups 5 and 6 Recruitment and intervention
and CBT-E groups 7 and 8 Recruitment and intervention
and CBT-E groups 9 and 10 Recruitment and intervention
and CBT-E groups 1 and 2 Follow-up (6 and 12 months)
and CBT-E groups 3 and 4 Follow-up (6 and 12 months)
and CBT-E groups 5 and 6 Follow-up (6 and 12 months)
and CBT-E groups 7 and 8 Follow-up (6 and 12 months)
and CBT-E groups 9 and 10 Follow-up (6 and 12 months)
ent and maintenance of the database x
n and publication of results
nitive behavioural therapy–enhanced, HAPIFED Healthy APproach to WeIght manageseverity of dietary restraint, eating, shape
and weight over concern. These are averaged
for a global score. Version 16.0 [18] of the
EDE was translated to Brazilian/Portuguese
by collaborators from the Federal University
of Rio de Janeiro (Silvia Freitas and José
Carlos Appolinario), by authors of this paper
(MAP, AC) and by a PROATA eating
disorder specialist (Christina Morgan – CM),
back-translated to English by a certified
translator and the final version approved by
one of the authors of EDE (O’Connor M).
The reliability and concurrent validity of the
translated EDE was tested and found to be
satisfactory. There was 80 % inter-interviewer
agreement (kappa 0.69) on the diagnosis
made with the EDE interview and 77.3 %
agreement (kappa 0.68) (unpublished data
provided by author AC). The diagnosis was
made according to the eating disorder
module of the Structured Clinical Interview
for DSM-IV Axis I Disorders-Patient Edition
(SCID-I/P) interview [35] (Portuguese
version) [36]. Small adjustments were made
by the author MAP, so that the Portuguese
version used in the study is now consistent
with the 17th version of the EDE [34], in
order to derive DSM-5 diagnoses.
2.2.2. Eating Disorder Examination Questionnaire
(EDE-Q) [37]: a self-report measure is
derived from the EDE interview. Like the
EDE, it has four subscales (dietary restraint,
eating, weight and shape concerns).
An unpublished Brazilian/Portuguese
translation of the more recent 28-itemc
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ment and Food in Eating Disorders
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prepared by CM and MAP, and this version
will be used. This translation utilised the
validated European Portuguese version of the
original 36-item EDE-Q [38], which was
then modified to be consistent with
Brazilian/Portuguese.
2.2.3. Loss of Control over Eating Scale (LOCES)
[39]: a 24-item self-report that examines the
presence of loss of control during the binge
eating episodes in the last 4 weeks. A
Brazilian/Portuguese translation and
assessment of psychometric properties
(factor analysis and convergent validity) has
been completed (da Luz et al., manuscript
submitted).
2.2.4. Binge Eating Scale (BES) [40]: a 16-item
self-report instrument that has been
translated and validated in a Brazilian
sample [41]. This scale evaluates the
presence and severity of binge eating. It has
adequate psychometric properties in the
Brazilian version, with a cut-off point of 17
for the screening of eating disorders in obese
individuals seeking treatment for weight loss.
2.3. General psychopathology instrument:
2.3.1. Depression, Anxiety and Stress Scale
(DASS-21) [42, 43] in a translated and
validated Brazilian/Portuguese version [44].
This self-report instrument measures the
presence and severity of depressive symptoms,
anxiety and stress.
2.4. Adaptive function:
2.4.1. Health-related quality of life will be
measured with the 12-item Short Form
Health Survey (SF-12) [45]. This is a
self-report questionnaire that measures
health-related quality of life, subdivided in
2 scales – Physical Health Component
Summary scales (PCS) and Mental Health
Component Summary scales (MCS). A
score lower than 30 on the MCS indicates
severe impairment in mental health, and a
score from 31 to 40 indicates moderate
impairment. This is a widely-used measure
with sound psychometric properties and has
been translated into Brazilian/Portuguese [46].
2.4.2. Disability will be assessed using a question
analogous to the ‘days out of role’ questions
employed in the Australian National Survey
of Mental Health and Well-Being [47].
Participants will be asked to record the
number of days after the following question:
During the past 4 weeks, on how many days,if any, were you unable to complete your
work, study or household responsibilities
because of any problem with your (physical
or emotional) health? This was translated by
the author MAP.3. Measures only at baseline and end-of-treatment.
The following medical pathology tests will be
performed at baseline and end-of-treatment only:
fasting circulating glucose, insulin, lipid profile,
liver function test, electrolytes, urea, creatinine and
uric acid.
4. Measures at end-of-treatment only.
4.1. Client/patient satisfaction questionnaire [48].
This eight-item scale assesses general satisfaction
with services. It has a high internal consistency
(α= 0.93) and correlates with therapist’s assessment
of client satisfaction and with early treatment drop
out. This was translated by the author MAP.
4.2. Participants will be asked which group,
experimental or control, they thought they were
in. When all participants have completed
12-month follow-up and data has been
processed, participants will be debriefed, and
full information will be provided about
HAPIFED and CBT-E.
Treatment fidelity
Participants will be assigned to therapists who conduct
both forms of treatment, to control for potential non-
specific therapist effects. An occupational therapist will
conduct two home-based sessions. In preparation for this
RCT, therapists experienced with CBT-E and HAPIFED
(PH, JS) have trained all therapists (psychologists, occupa-
tional therapist and dietitian) and conducted monthly tele-
phone supervision sessions for 2 pilot therapy groups, one
for CBT-E and one for HAPIFED (August 2014 to February
2015; da Luz et al., manuscript in preparation). In addition,
an onsite Brazilian therapist CM has undergone the Oxford
CBT-E online training. De-identified audio recordings were
made of all pilot sessions to assist with training. Supervision
of therapists during the trial will be provided by a meeting
each month with PH, with additional specialist supervision
by AS with expertise in appetite regulation and other spe-
cific approaches to weight management. Both therapies will
be conducted in accordance with the treatment manuals.
PH will visit Brazil twice a year for 3 years for face-to-face
meetings with the Brazilian team. A random 10 % sample
of de-identified digitally recorded audiotaped sessions will
be reviewed by AC for fidelity.
Data collection, management and analysis
Researchers conducting outcome data entry will be blind
to the study group of participants. Between-group out-
come analyses will not begin until after the final 1-year
Palavras et al. Trials  (2015) 16:578 Page 8 of 10follow-up. Governance of data and an independent Data
Monitoring Committee (DMC) responsible for interim
mid-point in recruitment safety and futility analyses of
de-identified data will be conducted at the University of
Western Sydney site. The DMC will be composed of a
biostatistician with expertise in RCTs, and two senior in-
dependent clinical researchers with expertise in RCTs.
The trial will be discontinued if assessed to be futile and/
or participants’ binge eating is increasing significantly
and/or attrition is over 50 %. Therapists under supervision
who are not blind to treatment arm will be responsible for
the safety of individual participants and will receive
directly any concerns about an individual from the DMC.
STATA (StataCorp, College Station, TX, USA) for most
statistics will be used. Baseline univariate between-group
tests will be done to compare groups on outcome vari-
ables, clinical and demographic data. Data will be analysed
following ‘intention-to-treat’ principles. Generalised esti-
mating equations [49] with a logit response function will
be used for dichotomous outcomes, such as achieving a
5 % reduction in body weight. Linear mixed effects model-
ling [50] will be used to test for between-group differences
in the continuous outcome measures, namely weight loss,
levels of ED symptom change, adaptive function, quality
of life, depression and anxiety levels, waist circumference,
blood pressure, and biochemical markers such as circulat-
ing lipid or glucose levels. Putative covariates will be diag-
nostic group (BN or BED) and use of psychotropic
medication. Predictors of outcomes at 6-month and 12-
month follow-up to be tested will include the rate of early
(by mid-treatment) reduction in binge eating.
Ethics and dissemination
The study has been approved by the Human Research
Ethics Committee of the Federal University of São Paulo,
Brazil (CAAE 43874315.4.0000.5505). Written informed
consent including information on confidentiality provi-
sions will be obtained from each subject. Only investigators
and authorised research personnel will have access to the
database. Reports will be made regularly to the committee
including results of interim safety analyses by the DMC.
The trial results will be submitted to a peer-reviewed
scientific paper, and authors will present results at ap-
propriate scientific meetings and community and advo-
cacy organisations, as well as being released to the
media following publication.
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist for recom-
mended items to address in a clinical trial protocol is
found as an additional file (see Additional file 1).
Discussion
HAPIFED adopts a new approach that integrates the
most effective treatment for BN and BED (CBT-E) withBWLT strategies that are most likely to lead to longer-
term weight loss [51]. It is the first such therapy pro-
posed that recognises that management of the person
who is obese and has an eating disorder needs to be of
increased intensity and duration if improved weight
management and sustained behavioural change is to be
achieved, similar to the intensity used in the under-
weight eating disorder patient [18].
The currently proposed study is a RCT with allocation
concealment. It is limited in that only blinding of partici-
pants (but not therapists) will be attempted. Single
blinding is being attempted by participants being in-
formed only that they will be randomised to either CBT-
E or HAPIFED group-based therapy of equal session
number and duration. They will not be informed of any
specific details of the therapy content. Whilst it is pos-
sible that patients familiar with psychological therapies
would correctly guess what type of therapy group they
are in, this may be less likely in Brazil where English lit-
eracy is not common and to our knowledge the CBT-E
manual has not been published in Portuguese. We will
also check for the success of the participant blinding.
The choice of control therapy for HAPIFED also has
some limitations. It was made on the basis that whilst
BWLT had been found to be efficacious and safe in BED
[26] longer-term outcomes compares less well to CBT [27]
and it is not known to be effective or safe in BN [26].
Therefore, CBT-E, the lead evidence-based therapy for BN,
an evidence-based therapy for BED and recommended by
international treatment guidelines, was chosen as our con-
trol therapy. CBT-E is, however, an active therapy akin to
‘standard care’ that controls for non-specific effects of ther-
apy and also for specific effects on reducing eating disorder
symptoms, but it is not a weight loss therapy. Thus, the
study is not able to determine the efficacy of weight loss in
HAPIFED compared to other weight loss treatments, but
only compared to a control condition without an active
weight loss component.
The expected outcomes and significance of this pro-
posed trial are that HAPIFED has the potential to improve
health outcomes for the rapidly increasing number of
people with obesity and eating disorders, and to help close
the treatment gap for adults with co-morbid eating and
weight disorders. Effective approaches to improve weight
management for this group will reduce the well-known
personal and community burden of obesity, as well as
the impact on health systems from physical (such as
high blood pressure) and mental health (such as de-
pression [52]) consequences of obesity. We anticipate
that this study will also inform the sample size re-
quired for future trials to show whether HAPIFED
can induce clinically significant weight loss while also
producing as great a benefit as CBT-E for the reduc-
tion of eating disorder symptoms.
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Recruitment, assessment and the first therapy groups
have commenced.
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